
115th CONGRESS 1st Session



To prevent conflicts of interest that stem from the revolving door that raises concerns about the independence of pharmaceutical regulators.

### IN THE SENATE OF THE UNITED STATES

Ms. BALDWIN introduced the following bill; which was read twice and referred to the Committee on \_\_\_\_\_

## A BILL

- To prevent conflicts of interest that stem from the revolving door that raises concerns about the independence of pharmaceutical regulators.
  - 1 Be it enacted by the Senate and House of Representa-
  - 2 tives of the United States of America in Congress assembled,

### **3** SECTION 1. SHORT TITLE.

- 4 This Act may be cited as the "Pharmaceutical Regu-
- 5 lation Conflict of Interest Act".

6 SEC. 2. REQUIREMENTS RELATING TO SLOWING THE RE7 VOLVING DOOR AMONG PHARMACEUTICAL
8 REGULATORS.

- 9 The Ethics in Government Act of 1978 (5 U.S.C.
- 10 App.) is amended by adding at the end the following:

# 1"TITLE VI—SPECIAL REQUIRE-2MENTS FOR PHARMA-3CEUTICAL REGULATORS

### 4 "SEC. 601. DEFINITIONS.

5 "(a) IN GENERAL.—In this title, the terms 'des6 ignated agency ethics official' and 'executive branch' have
7 the meanings given those terms under section 109.

8 "(b) OTHER DEFINITIONS.—In this title:

9 "(1) COVERED PHARMACEUTICAL REGU10 LATOR.—The term 'covered pharmaceutical regu11 lator' means an officer or employee of a covered
12 pharmaceutical regulatory agency who occupies—

13 "(A) a supervisory position classified at or
14 above GS-13 of the General Schedule;

"(B) in the case of a position not under
the General Schedule, a supervisory position for
which the rate of basic pay is not less than the
minimum rate of basic pay for GS-13 of the
General Schedule; or

20 "(C) any other supervisory position deter21 mined to be of equal classification by the Direc22 tor.

23 "(2) COVERED PHARMACEUTICAL REGULATORY
24 AGENCY.—The term 'covered pharmaceutical regu25 latory agency'—

1	"(A) means an agency whose primary re-
2	sponsibility is to regulate the manufacture, dis-
3	tribution, or sale of drugs (as defined in section
4	201 of the Federal Food, Drug, and Cosmetic
5	Act (21 U.S.C. 321)) or biological products (as
6	defined in section 351 of the Public Health
7	Service Act (42 U.S.C. 262)); and
8	"(B) includes—
9	"(i) the Drug Enforcement Adminis-
10	tration; and
11	"(ii) the Food and Drug Administra-
12	tion;
13	"(3) DIRECTOR.—The term 'Director' means
14	the Director of the Office of Government Ethics.
15	"(4) FORMER CLIENT.—The term 'former cli-
16	ent'—
17	"(A) means a person for whom the covered
18	pharmaceutical regulator served personally as
19	an agent, attorney, or consultant during the 2-
20	year period ending on the date (after such serv-
21	ice) on which the covered pharmaceutical regu-
22	lator begins service in the Federal Government;
23	and
24	"(B) does not include—

S.L.C.

1	"(i) instances in which the service
2	provided was limited to a speech or similar
3	appearance; or
4	"(ii) a client of the former employer
5	of the covered pharmaceutical regulator to
6	whom the covered pharmaceutical regu-
7	lator did not personally provide such serv-
8	ices.
9	"(5) FORMER EMPLOYER.—The term 'former
10	employer'—
11	"(A) means a person for whom a covered
12	pharmaceutical regulator served as an em-
13	ployee, officer, director, trustee, or general part-
14	ner during the 2-year period ending on the date
15	(after such service) on which the covered phar-
16	maceutical regulator begins service in the Fed-
17	eral Government; and
18	"(B) does not include—
19	"(i) any entity in the Federal Govern-
20	ment, including an executive branch agen-
21	cy;
22	"(ii) a State or local government;
23	"(iii) the District of Columbia;
24	"(iv) an Indian tribe, as defined in
25	section 4 of the Indian Self-Determination

25

S.L.C.

5

	5
1	and Education Assistance Act (25 U.S.C.
2	5304); or
3	"(v) the government of a territory or
4	possession of the United States.
5	"SEC. 602. CONFLICT OF INTEREST AND ELIGIBILITY
6	STANDARDS FOR PHARMACEUTICAL REGU-
7	LATORS.
8	"(a) IN GENERAL.—A covered pharmaceutical regu-
9	lator shall not make, participate in making, or in any way
10	attempt to use the official position of the covered pharma-
11	ceutical regulator to influence a particular matter that
12	provides a direct and substantial pecuniary benefit for a
13	former employer or former client of the covered pharma-
14	ceutical regulator.
15	"(b) Recusal.—A covered pharmaceutical regulator
16	shall recuse himself or herself from any official action that
17	would violate subsection (a).
18	"(c) WAIVER.—
19	"(1) IN GENERAL.—The head of the covered
20	pharmaceutical regulatory agency employing a cov-
21	ered pharmaceutical regulator, in consultation with
22	the Director, may grant a written waiver of the re-
23	strictions under subsection (a) if, and to the extent
24	that, the head of the covered pharmaceutical regu-

latory agency certifies in writing that—

6

"(A) the application of the restriction to 1 2 the particular matter is inconsistent with the 3 purposes of the restriction; or 4 "(B) it is in the public interest to grant 5 the waiver. 6 "(2) PUBLICATION.—The Director shall make 7 each waiver under paragraph (1) publicly available 8 on the Web site of the Office of Government Ethics. 9 "SEC. 603. NEGOTIATING FUTURE PRIVATE SECTOR EM-10 PLOYMENT. 11 "(a) PROHIBITION.—Except as provided in sub-12 section (c), and notwithstanding any other provision of 13 law, a covered pharmaceutical regulator may not participate in any particular matter which involves, to the knowl-14 15 edge of the covered pharmaceutical regulator, an individual or entity with whom the covered pharmaceutical 16 17 regulator is in negotiations of future employment or has 18 an arrangement concerning prospective employment. 19 "(b) DISCLOSURE  $\mathbf{OF}$ Employment NEGOTIA-20 TIONS.— 21 "(1) IN GENERAL.—If a covered pharmaceutical 22 regulator begins any negotiations of future employ-23 ment with another person, or an agent or inter-24 mediary of another person, or other discussion or 25 communication with another person, or an agent or

S.L.C.

 $\overline{7}$ 

1 intermediary of another person, mutually conducted 2 with a view toward reaching an agreement regarding 3 possible employment of the covered pharmaceutical 4 regulator, the covered pharmaceutical regulator shall 5 notify the designated agency ethics official of the 6 covered pharmaceutical regulatory agency employing 7 the covered pharmaceutical regulator regarding the 8 negotiations, discussions, or communications.

9 "(2) INFORMATION.—A designated agency eth-10 ics official receiving notice under paragraph (1), 11 after consultation with the Director, shall inform the 12 covered pharmaceutical regulator of any potential 13 conflicts of interest involved in any negotiations, dis-14 cussions, or communications with the other person 15 and the applicable prohibitions.

16 "(3) PUBLICATION.—The Director, after receiv-17 ing notice under paragraph (1), shall make publicly 18 available on the Web site of the Office of Govern-19 ment Ethics the name of the covered pharmaceutical 20 regulator and the name of the private person in-21 volved in the negotiations or arrangement con-22 cerning prospective employment of the covered phar-23 maceutical regulator.

24 "(c) WAIVERS ONLY WHEN EXCEPTIONAL CIR-25 CUMSTANCES EXIST.—

1	"(1) IN GENERAL.—The head of a covered
2	pharmaceutical regulatory agency may only grant a
3	waiver of the prohibition under subsection (a) if the
4	head determines that exceptional circumstances
5	exist.
6	"(2) REVIEW AND PUBLICATION.—For any
7	waiver granted under paragraph (1), the Director
8	shall—
9	"(A) review the circumstances relating to
10	the waiver and the determination that excep-
11	tional circumstances exist; and
12	"(B) make the waiver publicly available on
13	the Web site of the Office of Government Eth-
14	ics, which shall include—
15	"(i) the name of the private person in-
16	volved in the negotiations or arrangement
17	concerning prospective employment of the
18	covered pharmaceutical regulator; and
19	"(ii) the date on which the negotia-
20	tions or arrangement commenced.
21	"(d) SCOPE.—For the purposes of this section, the
22	term 'negotiations of future employment' is not limited to
23	discussions of specific terms or conditions of employment
24	in a specific position.

#### 1 "SEC. 604. RECORDKEEPING.

2 "The Director shall—

"(1) receive all employment histories, recusal
and waiver records, and other disclosure records for
covered pharmaceutical regulators necessary for
monitoring compliance with this title, and make
those records publicly available on the Web site of
the Office of Government Ethics;

9 "(2) promulgate rules and regulations, in con-10 sultation with the Director of the Office of Per-11 sonnel Management and the Attorney General, to 12 implement this title;

13 "(3) provide guidance and assistance where ap14 propriate to facilitate compliance with this title;

"(4) review and, where necessary, assist designated agency ethics officials in providing advice to
covered pharmaceutical regulators regarding compliance with this title; and

"(5) if the Director determines that a violation
of this title may have occurred, and in consultation
with the designated agency ethics official and the
Counsel to the President, refer the compliance case
to the United States Attorney for the District of Columbia for enforcement action.

### 25 "SEC. 605. PENALTIES AND INJUNCTIONS.

26 "(a) CRIMINAL PENALTIES.—

	10
1	"(1) IN GENERAL.—Any person who violates
2	section $602$ or $603$ shall be fined under title $18$ ,
3	United States Code, imprisoned for not more than
4	1 year, or both.
5	"(2) WILLFUL VIOLATIONS.—Any person who
6	will fully violates section $602$ or $603$ shall be fined
7	under title 18, United States Code, imprisoned for
8	not more than 5 years, or both.
9	"(b) Civil Enforcement.—
10	"(1) IN GENERAL.—The Attorney General may
11	bring a civil action in an appropriate district court
12	of the United States against any person who vio-
13	lates, or whom the Attorney General has reason to
14	believe is engaging in conduct that violates, section
15	602 or 603.
16	"(2) Civil penalty.—
17	"(A) IN GENERAL.—Upon proof by a pre-
18	ponderance of the evidence that a person vio-
19	lated section 602 or 603, the court shall impose
20	a civil penalty of not more than the greater
21	of—
22	"(i) \$100,000 for each violation; or
23	"(ii) the amount of compensation the
24	person received or was offered for the con-
25	duct constituting the violation.

1	"(B) RULE OF CONSTRUCTION.—A civil
2	penalty under this subsection shall be in addi-
3	tion to any other criminal or civil statutory,
4	common law, or administrative remedy available
5	to the United States or any other person.
6	"(3) Injunctive relief.—
7	"(A) IN GENERAL.—In a civil action
8	brought under paragraph (1) against a person,
9	the Attorney General may petition the court for
10	an order prohibiting the person from engaging
11	in conduct that violates section 602 or 603.
12	"(B) STANDARD.—The court may issue an
13	order under subparagraph (A) if the court finds
14	by a preponderance of the evidence that the
15	conduct of the person violates section $602$ or
16	603.
17	"(C) RULE OF CONSTRUCTION.—The filing
18	of a petition seeking injunctive relief under this
19	paragraph shall not preclude any other remedy
20	that is available by law to the United States or
21	any other person.".

1	SEC. 3. SLOWING THE REVOLVING DOOR FROM PHARMA-
2	CEUTICAL REGULATORY AGENCY INTO PRI-
3	VATE SECTOR REPRESENTATIONAL ACTIVI-
4	TIES.
5	(a) IN GENERAL.—Section 207 of title 18, United
6	States Code, is amended—
7	(1) by redesignating subsections (e) through (l)
8	as subsections (f) through (m), respectively; and
9	(2) by inserting after subsection (d) the fol-
10	lowing:
11	"(e) Restrictions on Employment for Pharma-
12	CEUTICAL REGULATORS.—
13	"(1) IN GENERAL.—In addition to the restric-
14	tions set forth in subsections (a), (b), (c), and (d),
15	a covered pharmaceutical regulator shall not—
16	"(A) during the 2-year period beginning on
17	the date on which his or her employment as a
18	covered pharmaceutical regulator ceases—
19	"(i) knowingly act as agent or attor-
20	ney for, or otherwise represent, any other
21	person for compensation (except the
22	United States) in any formal or informal
23	appearance before;
24	"(ii) with the intent to influence,
25	make any oral or written communication

1	on behalf of any other person (except the
2	United States) to; or
3	"(iii) knowingly aid, advise, or assist
4	in—
5	"(I) representing any other per-
6	son (except the United States) in any
7	formal or informal appearance before;
8	or
9	"(II) making, with the intent to
10	influence, any oral or written commu-
11	nication on behalf of any other person
12	(except the United States) to,
13	any court of the United States, or any offi-
14	cer or employee thereof, in connection with
15	any judicial or other proceeding, which was
16	actually pending under his or her official
17	responsibility as a covered pharmaceutical
18	regulator during the 1-year period ending
19	on the date on which his or her employ-
20	ment as a covered pharmaceutical regu-
21	lator ceases or in which he or she partici-
22	pated personally and substantially as a
23	covered pharmaceutical regulator; or

1	"(B) during the 2-year period beginning on
2	the date on which his or her employment as a
3	covered pharmaceutical regulator ceases—
4	"(i) knowingly act as a lobbyist or
5	agent for, or otherwise represent, any
6	other person for compensation (except the
7	United States) in any formal or informal
8	appearance before;
9	"(ii) with the intent to influence,
10	make any oral or written communication
11	or conduct any lobbying activities on behalf
12	of any other person (except the United
13	States) to; or
14	"(iii) knowingly aid, advise, or assist
15	in—
16	"(I) representing any other per-
17	son (except the United States) in any
18	formal or informal appearance before;
19	or
20	"(II) making, with the intent to
21	influence, any oral or written commu-
22	nication or conduct any lobbying ac-
23	tivities on behalf of any other person
24	(except the United States) to,

10
any department or agency of the executive
branch or Congress (including any com-
mittee of Congress), or any officer or em-
ployee thereof, in connection with any mat-
ter that is pending before the department,
the agency, or Congress.
"(2) PENALTY.—Any person who violates para-
graph (1) shall be punished as provided in section
216.
"(3) DEFINITIONS.—In this subsection—
"(A) the term 'covered pharmaceutical reg-
ulator' has the meaning given that term in sec-
tion 601 of the Ethics in Government Act of
1978 (5 U.S.C. App.); and
"(B) the terms 'lobbying activities' and
'lobbyist' have the meanings given those terms
in section 3 of the Lobbying Disclosure Act of
1995 (2 U.S.C. 1602).".
(b) Technical and Conforming Amendments.—
(1) Section 103(a) of the Honest Leadership
and Open Government Act of 2007 (2 U.S.C.
4702(a)) is amended by striking "section 207(e)"
each place it appears and inserting "section 207(f)".
(2) Section 207 of title 18, United States Code,
as amended by subsection (a), is amended—

1	(A) in subsection $(g)(1)$ , as so redesig-
2	nated, by striking "or (e)" and inserting "or
3	(f)";
4	(B) in subsection $(j)(1)(B)$ , as so redesig-
5	nated, by striking "subsection (f)" and insert-
6	ing "subsection (g)"; and
7	(C) in subsection (k), as so redesignated—
8	(i) in paragraph (1)(B), by striking
9	"(25 U.S.C. 450i(j))" and inserting "(25
10	U.S.C. 5323(j))";
11	(ii) in paragraph (2), in the matter
12	preceding subparagraph (A), by striking
13	"and (e)" and inserting "(e), and (f)";
14	(iii) in paragraph (4), by striking
15	"and (e)" and inserting "(e), and (f)"; and
16	(iv) in paragraph (7)—
17	(I) in subparagraph (A), by strik-
18	ing "and (e)" and inserting "(e), and
19	(f)"; and
20	(II) in subparagraph (B)(ii), in
21	the matter preceding subclause (I), by
22	striking "subsections (c), (d), or (e)"
23	and inserting "subsection (c), (d), (e),
24	or (f)".

1	(3) Section $141(b)(4)$ of the Trade Act of $1974$
2	(19 U.S.C. 2171(b)(4)) is amended by striking "sec-
3	tion $207(f)(3)$ " and inserting " $207(g)(3)$ ".
4	(4) Section $7802(b)(3)(B)$ of the Internal Rev-
5	enue Code of 1986 is amended by striking "and (f)
6	of section 207" and inserting "and (g) of section
7	207".
8	(5) Section 3105(c) of the USEC Privatization
9	Act (42 U.S.C. 2297h–3(c)) is amended by striking
10	"and (d)" and inserting "(d), and (e)".
11	(6) Section $106(p)(6)(I)(ii)$ of title 49, United
12	States Code, is amended by striking "and (f) of sec-
13	tion 207" and inserting "and (g) of section 207".
14	SEC. 4. SEVERABILITY.
15	If any provision of this Act or any amendment made
16	by this Act, or any application of such provision or amend-
17	ment to any person or circumstance, is held to be uncon-
18	stitutional, the remainder of the provisions of this Act and
19	the amendments made by this Act and the application of
20	the provision or amendment to any other person or cir-

 $21 \ \ {\rm cumstance \ shall \ not \ be \ affected.}$